Company: CI
Filing Date: 2025-09-04
Form Type: 424B5
Source: 0001140361-25-033868
Chunk: 11

Company: Cigna Group
Filing Date: 2025-09-04
Form: 424B5
Chunk 11
---
 a result, such underwriters or their affiliates may receive 5% or more of the net proceeds from this offering. Such underwriters would be deemed to have a conflict of interest within the meaning of Rule 5121 of the Financial Industry Regulatory Authority, Inc. (“FINRA Rule 5121”). Accordingly, this offering is being made in compliance with the requirements of FINRA Rule 5121. See “Use of Proceeds” and “Underwriting (Conflicts of Interest)” for additional information.

<div align='center'>S-4</div>

TABLE OF CONTENTS

SELECTED FINANCIAL INFORMATION The following table presents selected historical consolidated financial information of The Cigna Group. The selected historical consolidated financial information of The Cigna Group for the six-month period ended June 30, 2025 and each of the years ended December 31, 2024 and 2023, and as of December 31, 2024 and December 31, 2023, are derived from The Cigna Group’s consolidated financial statements and related notes included in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 and the audited consolidated financial statements and related notes contained in its Annual Report on Form 10-K for the year ended December 31, 2024, respectively, which are incorporated by reference into this prospectus supplement and the accompanying prospectus. The following selected historical consolidated financial information of The Cigna Group is only a summary and is not necessarily indicative of the results of future operations of The Cigna Group, and you should read such information in conjunction with (i) The Cigna Group’s consolidated financial statements, the notes related thereto and the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 and (ii) The Cigna Group’s audited consolidated financial statements, the notes related thereto and the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in its Annual Report on Form 10-K for the year ended December 31, 2024, each of which is incorporated by reference into this prospectus supplement and the accompanying prospectus. In particular, please refer to the notes to The Cigna Group’s audited consolidated financial statements and unaudited consolidated financial statements for significant events affecting the comparability of results as well as material uncertainties regarding The C